Amgen CEO named PhRMA board chairman-elect
WASHINGTON — The Pharmaceutical Research and Manufacturers of America has new officers on its board of directors. The organization has named Amgen chairman and CEO Robert Bradway to the chairman-elect position, effective immediately, and named two more industry executives to the board.
In addition to Bradway, Sanofi CEO Olivier Brandicourt will become chairman-elect and Astellas Americas president James Robinson will become treasurer, effective Feb. 7, 2018. Bradway, who was formerly board treasurer, succeeds Johnson & Johnson EVP and worldwide chairman pharmaceuticals Joaquin Duato as chairman-elect.
“I am pleased to welcome Bob to the board as our chairman-elect,” PhRMA president and CEO Stephen Ubl said. “Our companies are developing therapies unimaginable just a decade ago, and these advances will help many patients with serious and debilitating diseases. Together, we will ensure this innovation continues by advancing a comprehensive set of market-based reforms that improve access and affordability for patients.”
Bradway has been with Amgen since 2006, serving as CEO since 2012 and chairman since 2013. He also is the chairman of the CEO Roundtable on Cancer and is a member of Boeing’s board of directors. Brandicourt has been CEO of Sanofi since April 2015, joining the company from his post at Bayer Healthcare as a member of the executive leadership team. Robinson has led Astellas Americas since April 2016, having previously led its pharmaceuticals commercial in the organization in the United States. He joined the company in 2005 as VP health systems. Previously, he work with Schering-Plough, which was acquired by Merck in 2009.
“Now, more than ever, PhRMA member companies are bringing forth an unprecedented series of medical innovations to support human health,” Bradway said. Our innovations promise to not only improve and extend the lives of millions of patients, but also to positively bend the cost curve by decreasing the financial burden of serious diseases on society. I look forward to working together with stakeholders across the health care continuum to ensure a fertile environment for innovation and to encourage creative policy positions so that patients have access to the medicines they need.”
DSNTV: FlavoRx’s Baker on integrating flavoring, its role in building relationships
At this year’s National Association of Chain Drug Stores Total Store Expo, Drug Store News was walking the show floor talking to vendors about their potential as partners to retailers. In the first installment of four videos from NACDS TSE, DSN talks to FlavoRx SVP marketing Chad Baker about how the company helps pharmacies make medication more palatable for children and makes it easy for pharmacists to flavor medication by integrating it into existing reconstitution workflow. He also discusses the impact on the patient-pharmacist relationship that takes place as a result of the interaction that FlavoRx spurs.
“For pharmacies, now more than ever, they’re focused on that customer experience and really making sure that when customers come through the door they feel like they’re engaged with their pharmacist and a great relationship with the pharmacy team,” Baker said. “That’s what everyone talks about; that’s what we do — we provide a reason for these pharmacies to engage with their customers.”
Smith Drug adds associate VP strategic accounts
SPARTANBURG, S.C. — Smith Drug has a new addition to its staff. The company named Joe Willaman to the newly created position of associate VP strategic accounts. In the position, Willaman will work with regional chains to highlight the benefits of Smith Drug’s products and services.
“Joe joined our team two years ago and has made a significant impact on our business,” Smith Drug and Burlington Drug president Jeff Foreman said. “Joe’s experience in Strategic Programs are a natural fit for this market segment. He was integral in developing our pricing optimization program, which is a tremendous benefit for all of our customers.”
Willaman, a graduate of Ohio University, has previously worked in marketing at Cardinal Health and in generics, pricing and national accounts at McKesson.
“I am looking forward to the opportunity to lead this growth initiative,” Willaman said. “Smith Drug and Burlington Drug are known for the excellent service and support it gives to all of its customers, and I intend to see that our regional chain customers receive that same level of attention.”